Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BNTX 
BioNTech SE (BNTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/17/2025: BNTX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
21 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $136.05
1 Year Target Price $136.05
| 13 | Strong Buy |
| 3 | Buy |
| 5 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -26.4% | Avg. Invested days 29 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/17/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 24.98B USD | Price to earnings Ratio - | 1Y Target Price 136.05 |
Price to earnings Ratio - | 1Y Target Price 136.05 | ||
Volume (30-day avg) 21 | Beta 1.31 | 52 Weeks Range 81.20 - 129.27 | Updated Date 11/17/2025 |
52 Weeks Range 81.20 - 129.27 | Updated Date 11/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.78 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-03 | When - | Estimate -1.02 | Actual -0.12 |
Profitability
Profit Margin -18.13% | Operating Margin (TTM) -2.17% |
Management Effectiveness
Return on Assets (TTM) -2.3% | Return on Equity (TTM) -3.04% |
Valuation
Trailing PE - | Forward PE 7.04 | Enterprise Value 8190109709 | Price to Sales(TTM) 7.92 |
Enterprise Value 8190109709 | Price to Sales(TTM) 7.92 | ||
Enterprise Value to Revenue 2.23 | Enterprise Value to EBITDA 41.21 | Shares Outstanding 240455450 | Shares Floating 93871403 |
Shares Outstanding 240455450 | Shares Floating 93871403 | ||
Percent Insiders 61.84 | Percent Institutions 22.44 |
Upturn AI SWOT
BioNTech SE
Company Overview
History and Background
BioNTech SE was founded in 2008 in Mainz, Germany. It initially focused on individualized cancer immunotherapies before pivoting to mRNA technology. A significant milestone was the development and rapid deployment of the COVID-19 vaccine in partnership with Pfizer.
Core Business Areas
- mRNA-Based Therapies: Development of mRNA-based vaccines and therapeutics for infectious diseases, cancer, and other diseases.
- Cell Therapies: Development of cell therapies, including CAR-T cell therapies, for cancer treatment.
- Protein Therapeutics: Development of protein-based immunomodulators and antibodies.
Leadership and Structure
The leadership team includes CEO Uu011fur u015eahin and CFO Jens Holstein. The organizational structure comprises research, development, manufacturing, and commercial operations.
Top Products and Market Share
Key Offerings
- Comirnaty (COVID-19 Vaccine): COVID-19 vaccine developed with Pfizer. Generated significant revenue. Competitors include Moderna (MRNA), Novavax (NVAX), and AstraZeneca (AZN).
- OncoRNA (Cancer Therapies): mRNA-based cancer therapies in various stages of clinical development. Competitors depend on the specific cancer type and therapy, and include companies like Roche (RHHBY) and Merck (MRK).
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high R&D costs, stringent regulatory requirements, and long development timelines. It is driven by innovation in areas like genomics, proteomics, and personalized medicine.
Positioning
BioNTech is a leader in mRNA technology, particularly for vaccine development. It has a strong intellectual property portfolio and strategic partnerships with major pharmaceutical companies.
Total Addressable Market (TAM)
The mRNA therapeutics market is projected to reach billions of dollars. BioNTech is well-positioned to capture a significant share of this market.
Upturn SWOT Analysis
Strengths
- Innovative mRNA technology platform
- Successful development and commercialization of Comirnaty
- Strong partnerships with Pfizer and other pharmaceutical companies
- Robust pipeline of cancer therapies
- Experienced management team
Weaknesses
- High dependence on Comirnaty revenue
- Relatively unproven track record outside of vaccines
- Reliance on partnerships for commercialization
- Manufacturing capacity constraints
Opportunities
- Expansion of mRNA technology into new therapeutic areas
- Development of personalized cancer vaccines
- Strategic acquisitions to expand pipeline and capabilities
- Increasing demand for preventative vaccines
- Growing cancer therapeutics market
Threats
- Competition from other biotechnology and pharmaceutical companies
- Patent disputes and intellectual property challenges
- Regulatory hurdles and changes in government policies
- Clinical trial failures
- Decline in COVID-19 vaccine demand
Competitors and Market Share
Key Competitors
- MRNA
- LLY
- GILD
Competitive Landscape
BioNTech's advantage lies in its validated mRNA technology and partnership with Pfizer. Challenges include competition from established pharmaceutical companies and the need to diversify its revenue streams.
Growth Trajectory and Initiatives
Historical Growth: BioNTech experienced exponential growth due to the success of the COVID-19 vaccine.
Future Projections: Analysts project continued growth, driven by the expansion of the mRNA platform into other therapeutic areas.
Recent Initiatives: BioNTech is investing heavily in research and development, expanding its manufacturing capacity, and pursuing strategic collaborations.
Summary
BioNTech is a strong player in the mRNA technology space, largely due to its successful COVID-19 vaccine. However, the company's future success depends on its ability to diversify its product pipeline and leverage its technology for other therapeutic areas. Declining vaccine demand and increasing competition pose potential risks. BioNTech should continue investing in R&D and strategic partnerships to maintain its competitive edge.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company reports
- Analyst estimates
- Industry publications
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Market conditions and company performance can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BioNTech SE
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2019-10-10 | Co-Founder, CEO & Chair of the Management Board Dr. Ugur Sahin M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 6772 | Website https://www.biontech.de |
Full time employees 6772 | Website https://www.biontech.de | ||
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.